Last updated on November 2018

Hypofractionated Radiosurgery for Localised Prostate Cancer


Brief description of study

Hypofractionated radiosurgery has been investigated in a few trials and appears to be safe and feasible.

Investigators initiated this multicenter phase II prospective trial to analyse feasibility (toxicity) of hypofractionated radiosurgery with 5 fractions in patients with localised prostate cancer, who are ineligible for the "PREFERE trial" under the hypothesis that the ratio of patients with late toxicity grade 2 after 1 year amounts 2,8% and is significant lower than 17.5%.

Detailed Study Description

Experimental radiosurgery of prostate with 5 fractions each with 7,00 Gy (total application rate of 35,00 Gy).

Planned visits are: Baseline, visits at every radiation day and four follow ups (4-6 weeks, 3 months, 6 months and one year after last day of radiation).

Clinical Study Identifier: NCT02635256

Contact Investigators or Research Sites near you

Start Over

Christian Keller, MD

University Hospital Frankfurt, Department of Radiation Therapy and Oncology
Frankfurt am Main, Germany
7.74miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.